Volume 21, Issue 1

Dear ECCO Family, In this interview, I had the pleasure of speaking with Professor Tarkan Karakan, an experienced clinician working in inflammatory bowel disease in a low- and middle-income country setting. Our conversation explored the practical realities of diagnosing and managing IBD, including limited healthcare resources, access to advanced therapies, and diagnostic infrastructure.

Dear ECCO Family, In this interview, Nicolas Avellaneda had the pleasure of speaking with Karin Davidson, a nurse from South Africa who participated in the development of the ECCO consensus on the management of inflammatory bowel disease (IBD) in low- and middle-income countries (LMICs).

Dear ECCO Friends and Family, In this new episode of Meet the JCC Authors, I had the pleasure of speaking with Sara El Ouali about her recent publication in the Journal of Crohn’s and Colitis titled: “Ustekinumab for ileal stricturing Crohn’s disease—an international multicenter retrospective cohort study.”

Johnson & Johnson sponsored two satellite symposia at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO 2026). These symposia were predominantly based on practical and engaging patient case studies that showed how guselkumab clinical trial data can be applied in real-world inflammatory bowel disease (IBD) care. The goal was to give clinicians actionable, evidence-based guidance for IBD management.